Is antivitamin K reversal required in patients with cirrhosis undergoing liver transplantation?

Background Antivitamin K agent (AVK) reversal in patients with cirrhosis awaiting liver transplantation (LT) is not defined in guidelines. We investigated the effect of reversion with prothrombin complex concentrate (PCC) on intraoperative transfusion, bleeding, and safety in LT patients on AVK. Study design and methods In 511 patients undergoing LT, we identified 25 patients treated with AVK (AVK group) and 13 patients with incidental portal vein thrombosis (PVT) without AVK (incidental PVT group). Fifty patients who underwent LT without PVT or AVK matched by age, model for end stage of liver disease (MELD), body mass index (BMI), and cirrhosis etiology were selected as the control group. Results There were no significant differences between the three groups in intraoperative blood loss, transfusion, and postoperative bleeding. In the AVK group, there were no differences between patients who received PCC and those who did not in intraoperative blood loss, red blood cells, fibrinogen, and platelet transfusion, or postoperative bleeding. PCC use had no effect on RBC transfusion in patients who had international normalized ratio or clotting time above versus below median values of the two parameters at baseline (2.3 and 103 s, respectively). No thrombotic events were detected in patients who received PCC. Discussion These data suggest that systematic administration of PCC to revert AVK prior to LT should be reconsidered.

Automated summary

The systematic administration of PCC to revert AVK prior to LT may not be necessary, as the study found no significant differences in intraoperative blood loss, transfusion, and postoperative bleeding between patients who received PCC and those who did not. Additionally, no thrombotic events were observed in patients who received PCC, suggesting its safety in this context.